Report

Medicines in Development for Alzheimer's Disease 2017 Report

PhRMA September 20, 2017

America’s biopharmaceutical research companies are investigating or developing 85 medicines to help the more than 5 million patients in the United States who are living with Alzheimer’s disease. The medicines in development are all in either clinical trials or under review by the Food and Drug Administration.

Alzheimer’s is one of the most complex diseases researchers have ever studied. There are many reasons Alzheimer’s research is so challenging. To start, the brain is the most complex and inaccessible organ in the body and the disease is correspondingly complicated. However, as our understanding of the disease grows so does our ability to find new potential treatment approaches and, ultimately, effective new medicines.

Download